General Medicine Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-11-2024
- Paid Up Capital ₹ 0.10 M
as on 15-11-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 48.42%
(FY 2023)
- Profit -1700.74%
(FY 2023)
- Ebitda -98.30%
(FY 2023)
- Net Worth -49.97%
(FY 2023)
- Total Assets 83.30%
(FY 2023)
About General Medicine Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravinder Prajapati and Ajay Prajapati serve as directors at the Company.
- CIN/LLPIN
U24290DL2019PTC344273
- Company No.
344273
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jan 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does General Medicine Therapeutics Private Limited offer?
General Medicine Therapeutics Private Limited offers a wide range of products and services, including Vitamins & Supplements, Multivitamins, Mineral Supplements.
Who are the key members and board of directors at General Medicine Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravinder Prajapati  | Director | 11-Jan-2019 | Current |
| Ajay Prajapati | Director | 11-Jan-2019 | Current |
Financial Performance of General Medicine Therapeutics.
General Medicine Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.42% increase. The company also saw a substantial fall in profitability, with a 1700.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 49.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of General Medicine Therapeutics?
In 2023, General Medicine Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
General Medicine Health Care Private LimitedActive 5 years 9 monthsRavinder Prajapati and Ajay Prajapati are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at General Medicine Therapeutics?
Unlock and access historical data on people associated with General Medicine Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of General Medicine Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped General Medicine Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
